Coulter Partners successfully led a search assignment for Oral Care AB and is pleased to announce the placement of Lucas Kromann as Chief Executive Officer (CEO) Denmark.
Coulter Partners successfully led a search for Babraham Research Campus Ltd (BRCL) and is pleased to announce the placement of Dr. Rich Ferrie as Chief Executive Officer (CEO).
Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, has appointed Edwin Moses as Chair of the Board of Directors, with immediate effect.
Some of the UK’s most ambitious early-stage life science companies are choosing Victoria House as their London base, adding fresh momentum to one of the capital’s most exciting life science communities.
In this guest blog, Dan Stanton, Trade Media Expert at Sartorius Bioprocess Solutions, discusses how tight funding, manual tech transfer and product specific analytics are keeping cell and gene therapies (CGTs) from realising their potential.
I’m pleased to share that we are part of a new Government and industry joint taskforce to drive innovation in the UK’s commercial environment for medicines, announced last week as part of government ambitions for the Life Sciences Strategy.
Senior figures from across industry, academia, investment and government met at the House of Lords, for a roundtable hosted by The Lord Ranger of Northwood to discuss the findings of a new report.
The launch of the NIHR Industry hub last week, the launch of UKRI/Innovate strategy this Thursday and a landmark Mansion House event tomorrow all signal forward momentum on Industrial Strategy.
SignaCor Therapeutics has been named the winner of Discovery Park's startup growth programme for innovations in cardiovascular health, securing £250k in funding from venture capital firm Zinc.
In this blog, Jane Wall, Managing Director at BIA, reflects on the insights from our sell-out Women in Biotech 'Big WiB' event held at Hinxton Hall, Cambridge, in the lead-up to International Women’s Day.